Cybin (CYBN.NE) is in a prime position as the push for psychedelic medicine surges across North America and around the world. Scientific evidence supports the life-changing impact of medicinal…
CYBN.NE
Cybin (CYBN.NE) announced they have entered a drug development agreement with Catalent (NYSE: CTLT). Catalent is a global provider for advanced delivery technologies, development, and manufacturing solutions for…
Cybin (CYBN.NE) announced they had completed their 20th pre-clinical study and are progressing their CYB003 and CYB004 proprietary psychedelic molecules into studies that will enable them to be tested…
Shamans among the machines In his 1999 lecture titled ‘Shamans Among the Machines’ Terence McKenna pointed out that “as far as people and machines are concerned, it was Ludwig…
Canada: not a big push for rec Canada is a country typically at the forefront of forward-thinking movements in health and science. With the recent legalization of cannabis…
Cybin (CYBN.NE) is popping up on our breakout screeners, as the stock approaches the $1.50 resistance zone and is primed for a run. The technical pattern here is called…
Cybin’s (CYBN.NE) subsidiary Adelia Therapeutics completed earnout milestones originally set in a contribution agreement for the period of January 1, 2021, following Cybin’s acquisition of Adelia. There are a…
Cybin (CYBN.NE) has announced they have been uplisted, moving from the OTC Pink to the OTCQB Venture Market, and will begin trading on the OTCQB when the market opens…
Ego death for ex. mining & cannabis CEOs Young and inexperienced Tony Robbins sociopaths are running about half of the current 37 publicly traded psychedelics companies. They are raising…